Domov › Rak jajčnikov › New York › New York City
Klinične študije za Rak jajčnikov v New York City, NY
69 študij za Rak jajčnikov išče udeležence na lokacijah v New York City in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Vključevanje udeležencevFaza 1/2
- Research Site, New York
- Research Site, New York
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
Vključevanje udeležencevFaza 2/3
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- Memorial Sloan Kettering Cancer Center, New York
Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients
Vključevanje udeležencev
- Memorial Sloan Kettering at Ralph Lauren Center (Limited Protocol Activities), New York
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Vključevanje udeležencevFaza 2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- Mount Sinai Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of PHST001 in Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- Mount Sinai, New York
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Vključevanje udeležencevFaza 1
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
- Icahn School of Medicine at Mount Sinai, New York
- in še 2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Vključevanje udeležencevFaza 1/2
- Columbia University Medical Center, New York
- Memorial Sloan Kettering, New York
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Vključevanje udeležencevFaza 2
- Memorial Sloan Kettering Hospital, New York
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
Vključevanje udeležencev
- Mount Sinai Health System, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Vključevanje udeležencevFaza 1
- Research Site, New York
Study of AVZO-021 in Patients With Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- Avenzo Therapeutics Recruiting Site, New York
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Vključevanje udeležencevOpazovalna študija
- NYU Langone Medical Center, New York
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Vključevanje udeležencevFaza 1/2
- Columbia University Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Vključevanje udeležencevFaza 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Vključevanje udeležencevFaza 3
- Laura and Isaac Perlmutter Cancer Center, New York
- Icahn School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Vključevanje udeležencevFaza 1
- New York University (NYU) Clinical Cancer Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
Vključevanje udeležencevFaza 2
- Columbia University Medical Center /ID# 277990, New York
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Vključevanje udeležencevFaza 1/2
- Columbia University, New York
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Vključevanje udeležencevFaza 1
- Memorial Sloan Kettering Cancer Center Head Neck Services, New York
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
Vključevanje udeležencevFaza 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Vključevanje udeležencevFaza 3
- Memorial Sloan Kettering Cancer Center ( Site 0072), New York
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Vključevanje udeležencevFaza 2
- Laura and Isaac Perlmutter Cancer Center, New York
A Study of Isoquercetin in People With Ovarian Cancer
Vključevanje udeležencevFaza 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Vključevanje udeležencevFaza 1/2
- Mount Sinai, New York
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
Vključevanje udeležencevFaza 3
- Columbia University Medical Center, New York
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Vključevanje udeležencevFaza 1
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- New York University (NYU) Clinical Cancer Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Vključevanje udeležencevFaza 3
- Laura and Isaac Perlmutter Cancer Center ( Site 0076), New York
Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer
Vključevanje udeležencevFaza 1/2
- Start Nyli, New York
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
Vključevanje udeležencevFaza 1/2
- Memorial Sloan Kettering Cancer Center, New York
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Vključevanje udeležencevFaza 1
- New York Cancer & Blood Specialists, New York
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- Icahn School of Medicine at Mount Sinai, New York
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Vključevanje udeležencevFaza 1/2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Vključevanje udeležencevFaza 1
- Memorial Sloan Kettering Cancer Center, New York
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- Memorial Sloan Kettering Cancer Center, New York
Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- Xencor Investigative Site, New York
Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer
Vključevanje udeležencevFaza 1/2
- Icahn School of Medicine at Mount Sinai Division of Hematology and Medical Oncology, New York
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Vključevanje udeležencev
- Mount Sinai Chelsea, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- Mount Sinai West, New York
- in še 4
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Vključevanje udeležencevFaza 3
- Mount Sinai Chelsea, New York
- Bellevue Hospital Center, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- in še 3
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Vključevanje udeležencevFaza 1/2
- NYU Langone Health, New York
- Icahn School of Medicine At Mount Sinai Prime, New York
Clinical Pre-screening Protocol for Ovarian Cancer
Vključevanje udeležencevOpazovalna študija
- The Blavatnik Family-Chelsea Medical Center at Mount Sinai, New York
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Vključevanje udeležencevFaza 2/3
- NYU Langone Health, New York
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Vključevanje udeležencevFaza 2
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Vključevanje udeležencevFaza 1
- Investigative Site #103, New York
- Investigative Site #106, New York
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
Vključevanje udeležencevFaza 3
- Mount Sinai, New York
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
Vključevanje udeležencevFaza 1/2
- Mt Sinai Hospital, New York
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Vključevanje udeležencevFaza 2
- Memorial Sloan Kettering Cancer Center, New York
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists, New York
- Columbia University Irving Medical Center, New York
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Vključevanje udeležencevFaza 3
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University, New York
A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)
Vključevanje udeležencev
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Vključevanje udeležencevFaza 1/2
- New York University Langone Health, New York
- ICHAN School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Vključevanje udeležencevFaza 1/2
- NYU Langone Medical Center, New York
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Vključevanje udeležencevFaza 1/2
- Memorial Sloan Kettering Cancer Center, New York
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Vključevanje udeležencevFaza 2
- USA04-0, New York
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Vključevanje udeležencevFaza 1/2
- Memorial Sloan Kettering Cancer Center, New York
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Vključevanje udeležencevFaza 3
- Memorial Sloan-Kettering Cancer Center, New York
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
Vključevanje udeležencevFaza 1
- Site 0173, New York
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
Vključevanje udeležencev
- Mount Sinai Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
Vključevanje udeležencevFaza 2
- Memorial Sloan Kettering Cancer Center (All protocol activities), New York
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Vključevanje udeležencevFaza 1/2
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
Vključevanje udeležencevFaza 1
- Memorial Sloan Kettering Cancer Center, New York
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Vključevanje udeležencevFaza 1
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
Vključevanje udeležencevFaza 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- NYU Cancer Institute Clinical Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Vključevanje udeležencevOpazovalna študija
- Massive Bio SYNERGY-AI site, New York
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- Exelixis Clinical Site #5, New York
NYSCF Scientific Discovery Biobank
Vključevanje udeležencevOpazovalna študija
- New York Stem Cell Foundation Research Institute, New York
Comprehensive Outcomes for After Cancer Health
Vključevanje udeležencevVabljeni zdravi prostovoljci
- Memorial Sloan Kettering Cancer Center, New York
Študije za Rak jajčnikov v drugih mestih
- Houston, TX89 študij
- Boston, MA61 študij
- Los Angeles, CA50 študij
- Nashville, TN49 študij
- Arlington, VA46 študij
- Philadelphia, PA44 študij
- Columbus, OH39 študij
- St. Louis, MO38 študij
- Chicago, IL36 študij
- San Antonio, TX31 študij
- Cleveland, OH30 študij
- Pittsburgh, PA30 študij
Druge študije v New York City
- Rak dojke136 študij
- Nemalicelični pljučni rak121 študij
- Rak (vse vrste)109 študij
- Rak prostate103 študij
- Metastatski rak93 študij
- Kolorektalni rak78 študij
- Rak pljuč60 študij
- Množni mielom60 študij
- Rak trebušne slinavke60 študij
- Rak endometrija52 študij
- Akutna mieločna levkemija51 študij
- Srčno popuščanje51 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.